Related Experiment Video
Updated: Oct 10, 2026

A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs
Published on: February 2, 2024
Integrilin, Intervention, and the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
Thel1
1Division of Cardiology, National Naval Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889, USA.
Abstract:
Eptifibatide (Integrelin, Corr Therapeutics, South San Francisco, CA) is a cyclic heptapeptide competitive inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that has a short half-life. The results of the initial dose-finding and phase III trials are reviewed and the ongoing Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial are described.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Peripheral Artery Disease III: Interprofessional Care
Dipeptidyl Peptidase 4 Inhibitors
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

